Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

Item 8.01. Other Events

On March31, 2017, Axsome Therapeutics,Inc. (the Company) updated
its presentation slide deck in preparation for a presentation by
Herriot Tabuteau, M.D., Chief Executive Officer of the Company,
at the 16th Annual Needham Healthcare Conference (the Conference)
on April5, 2017. Dr.Tabuteau will be presenting at the Conference
to provide an overview of the Companys business and late-stage
clinical product candidates, AXS-05 and AXS-02.

Included in the new corporate slide deck is updated financial
guidance from the Company in connection with its previously
disclosed March2017 public offering of common stock (the
Offering). The Company now believes that with the net proceeds
from the Offering, together with previously existing cash, it
will have sufficient funds to meet its anticipated operating cash
requirements into the first quarter of 2019. The Company has
based this estimate on assumptions that may prove to be wrong and
it could spend its available financial resources faster than it
currently expects.

Attached as Exhibit99.1 to this Current Report on Form8-K is a
copy of the presentation slide deck to be used in connection with
the planned presentation.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

About Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Recent Trading Information

Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed its last trading session down -0.30 at 3.90 with 237,134 shares trading hands.